Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, d...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T.Y. Kim
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors T.Y. Kim1, C.-. Yen2, S.-. Al-Batran3, L. Gao4, D. Ferry4, Y. Hsu4, R. Cheng5, M. Orlando6, A. Ohtsu7
  • 1Seoul National University Hospital, Seoul, Republic of Korea, /
  • 2National Cheng Kung University Hospital, Tainan, Taiwan, /
  • 3Krankenhaus Nordwest, Frankfurt, Germany, /
  • 4Eli Lilly and Company, Bridgewater, New Jersey, USA, /
  • 5Eli Lilly and Company, Taipei, Taiwan, /
  • 6Eli Lilly and Company, Buenos Aires, Argentina, /
  • 7National Cancer Center Hospital East, Kashiwa, Japan, /

Abstract

RAINBOW showed that adding 8 mg/kg ramucirumab to weekly paclitaxel (80 mg/m2) led to significant improvements in progression-free survival (PFS), overall survival (OS), and response rate. The exposure-response relationship of ramucirumab in East Asian patients from the RAINBOW trial was evaluated.